Form 4: Vistagen Therapeutics Director Rotunno Granted Stock Options
SEC Form 4 Filing
Mary L. Rotunno, a director at Vistagen Therapeutics, acquired 12,500 stock options on March 4, 2024, according to a Form 4 filing.
Summary
- Mary L. Rotunno, a director of Vistagen Therapeutics, Inc., filed a Form 4 disclosing a transaction involving derivative securities.
- On March 4, 2024, Rotunno acquired 12,500 stock options with an exercise price of $4.85.
- These options vest in twelve equal monthly installments starting from the grant date and expire on March 4, 2034.
- Rotunno also has a power of attorney agreement in place, allowing Shawn K. Singh and Cynthia Anderson to execute and file SEC forms on her behalf.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any explicit positive or negative sentiment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of directors with those of shareholders.
Stakeholder Impact
- The granting of stock options to a director aligns their interests with those of shareholders, potentially incentivizing them to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 2023-09-11 | Date of Power of Attorney execution by Mary Rotunno. |
| 2024-03-04 | Date of the stock option grant to Mary Rotunno. |
| 2024-03-06 | Date of Form 4 filing. |
| 2034-03-04 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.